Transforming care across a range of relapsed and refractory large B-cell lymphomas with demonstrated long-term efficacy and
flexibility for ambulatory delivery^1-5

Introducing Breyanzi^®▼ (lisocabtagene maraleucel)

Available for a broad range of LBCL patients − and the only CAR T-cell therapy available for 2L+ PMBCL, 2L+ FL3B and 3L+ FL^1,2*

Efficacy in 2L and 3L+ LBCL sustained through 4 and 5 years, respectively, with a potential for long-term survival^4–9

ICU admission rate of 4% in the TRANSFORM study⁶

A safety profile that allows for the flexibility of inpatient and ambulatory delivery^1–5

Explore Breyanzi

About Breyanzi

A concise overview of Breyanzi covering eligibility, how it works, and key clinical trial outcomes.

Overview of Breyanzi, including who it’s for (indication, NICE recommendation, referral eligibility), how it works and is manufactured, plus a summary of clinical efficacy and safety data.

Case Studies

In-depth insights from industry experts.

Consultants share real-world experiences of diagnosis, first-line treatment and initial response, follow-up, recurrence and management.

Video Series

Resources

Prescribing Information

Want to learn more about BREYANZI (lisocabtagene maraleucel)? Sign up to recieve marketing communications.

Licensed indication:¹

BREYANZI^®(lisocabtagene maraleucel) is indicated for the treatment of adult patients with DLBCL, HGBCL, PMBCL and FL3B, who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

BREYANZI^® is indicated for the treatment of adult patients with relapsed or refractory DLBCL, PMBCL and FL3B, after two or more lines of systemic therapy.

BREYANZI^® is indicated for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy.

BREYANZI^® is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor.

2L, second-line, 3L, third-line, CAR T, chimeric antigen receptor T-cell, DLBCL, diffuse large B-cell lymphoma, FL, follicular lymphoma, FL3B, follicular lymphoma grade 3B, HGBCL, high grade B-cell lymphoma, LBCL, large B-cell lymphoma, PMBCL, primary mediastinal large B-cell lymphoma.

References

BREYANZI^®(lisocabtagene maraleucel) UK Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/product/100499/smpc .
NICE TA1048. 26 March 2025. Available at https://www.nice.org.uk/guidance/TA1048.
NICE GID-TA11823. Available at https://www.nice.org.uk/guidance/indevelopment/gid-ta11823
Abramson JS, et al. Blood. 2023;141(14):1675–84; and supplementary appendix.
Kamdar M, et al. Poster presentation ASH 2025; Poster 3710.
Kamdar M, et al. Lancet. 2022;399(10343):2294–308; and supplementary appendix.
Kamdar M, et al. J Clin Oncol. 2025; 43(24):2671–8.
Abramson JS, et al. Lancet. 2020;396(10254):839–52; and supplementary appendix.
Abramson JS, et al. Poster presentation ASH 2024; Poster 3125.

2009-GB-2600038 | July 2026